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1967.---Female CBA mice were used to determine the effect of the glucose inhibitors, 2-deoxy-n-glucose and 2-amino-2-deoxy-oglucose on gold thioglucose-induced hypothalamic obesity. A marked inhibition in the incidence of obesity resulted when gold thioglucose was administered to mice receiving 2-deoxyn-glucose (I g/kg body wt) or 2-amino-2-deoxy-n-glucose (3 g/kg body wt). Gold d eposits at the site of the hypothalamic lesion were readily observed, after neutron activation using autoradiographic techniques, in all gold thioglucose-treated animals. These deposits were more extensive in obese than in nonobese mice. The results indicated that 2-deoxy-D-glucose and its amino analogue interact with cells in the "satiety center" to inhibit gold thioglucose-induced hypothalamic damage and obesity. In a separate study, a pronounced hyperphagic response was noted while 2-deoxy-n-glucose was administered to control (untreated) animals. This finding tends to further support the contention that a-deoxy-n-glucose interacts with cells in the satiety center. glucose inhibitors; food intake regulation; autoradiography T HE SYNDROME OF HYPERPHAGIA and obesity in mice after the administration of gold thioglucose was first reported in 1949 (6). Marshall et al. (23) later established that gold .thioglucose damaged hypothalamic neurons known to be associated with satiety in normal feeding behavior.
The administration of other gold compounds, such as gold thiogalactose and gold thiomalate, failed to induce comparable hypothalamic damage and obesity (24, 25) . These observations support the glucostatic theory of the regulation of food intake (25). In the earlier study, Debons et al. (8) obtained further evidence in support of this theory by demonstrating, using neutron activation and autoradiographic techniques, the full extent of gold deposition at the site of the hypothalamic lesion.
It is well established that 2-deoxy-D-glucose and 2-amino-2-deoxy-D-glucose inhibit the intracellular transfer and oxidation of glucose in peripheral and central nervous tissue (16, I 7, 31, 32, 33) and elevate blood glucose levels (7, I 6, I 7). The amount of 2-amino-20 deoxy-p-glucose needed to inhibit glucose metabolism has been shown in in vivo studies to be three to five times that required of 2-deoxy-D-glucose (3, 32, 33) . This may be attributed to steric factors which are known to play an important role in the rates of entry and metabolism of these glucose analogues (I I, I 8, 26) . Phosphorylated derivatives of these glucose antimetabolites are unable to serve as metabolic substrates for either the phosphohexose-isomerase or glucose 6-phosphate dehydrogenase reaction (29, 34 ). In the work to be reported we investigated the effect of n-deoxy-D-glucose and 2-amino-2-deoxy-p-glucose on gold thioglucose-induced hypothalamic hyperphagia and obesity in mice.
MATERIALS AND METHODS
Animal studies. Animals used in the following experiments were 7-to g-week-old female CBA mice weighing 20-25 g. They were fed Purina laboratory chow ad lib. and given tap water. Room temperature, which could not be controlled, varied from 20 to 27 C under the experimental conditions reported. Temperature was recorded daily by means of a Taylor thermograph. The effect of glucose inhibitors, a-deoxy-D-glucose and 2-amino-2-deoxy-p-glucose, on hypothalamic hyper-phagia and obesity induced by gold thioglucose was investigated in three separate experiments (experiments 1-3). Mice were assigned at random to six groups: I) control, 2) gold thioglucose, 3) 2-deoxy-n-glucose, 4) 2-deoxy-nglucose and gold thioglucose, 5) 2-amino-a-deoxy-nglucose, and S) 2-amino-2-deoxy-D-glucose and gold thioglucose.
Each cage contained seven or eight animals. Control and gold thioglucose-treated mice were given four intraperitoneal injections of demineralized water at 3-hr intervals, followed by four additional injections at 6-hr intervals.
Groups treated with glucose inhibitor and glucose inhibitor plus gold thioglucose were given these materials dissolved in a minimum amount of water on the same schedule.
In each of the eight injections, 2-deoxy-n-glucose5 was given at I g/kg body wt. The glucose inhibitor 2-amino-a-deoxy-D-glucose6 was given at 2 g/kg body wt in experiment I, and at 3 g/kg body wt in experiments 2 and 3. Animals which received gold thioglucose (800 mg/kg body wt) were given this drug intraperitoneally in a single injection 2 hr after the third injection of water or inhibitor.
In other studies, daily gain in weight and food intake responses of animals given glucose inhibitor administration were investigated.
One hundred mice (5 animals/ cage) were assigned at random to four groups: I) control -no water injection, 2) control-water injection, 3) 2-deoxy-n-glucose, and 4) 2-amino-2-deoxy-D-glucose. Demineralized water and glucose inhibitors were given intraperitoneally in the manner and at the dosage described earlier for experiments 2 and 3. Mice were maintained on trial for g days. Daily gain in weight and food intake were recorded.
Food intake was measured in a manner described earlier. 
RESULTS
Effects of inhibitor treatment on obesity induced by gold thioglucose. Results of experiments r-3, designed to test the effects of a-deoxy-D-glucose and a-amino-rr-deoxy-nglucose on gold thioglucose-induced hyperphagia and obesity, are given in Tables I and 2 and shown in Fig. I In experiment I, treatment of animals with 2-deoxy-nglucose (I g/kg body wt) appeared to lower the incidence of obesity following gold thioglucose. The administration of 2-amino-2-deoxy-D-glucose (2 g/kg body wt) failed to reduce the incidence of gold thioglucose induced obesity. Although the response of 2-deoxy-D-glucose on the reduction of obesity in this experiment was found not to be statistically significant on chi-square analysis, the finding was of sufficient biological interest to pursue these studies further under conditions where the variability in production of obesity by gold thioglucose could be controlled. In experiment z and, of particular interest, experiment 3, under conditions in which the variability in response of untreated control animals to gold thioglucose was controlled ( IOO % obesity), animals which received 2-deoxy-n-glucose (I g/kg body wt) or a-amino-2-deoxyn-glucose, at 3 g/kg body wt, exhibited a significant reduction in the incidence of obesity induced by gold thioglucose.
We have also noted (unpublished data) that, under the conditions of experiment 3, 2-deoxy-n-glucose (I g/kg) or 2-amino-2-deoxy-n-glucose (3 g/kg) given in a single intraperitoneal injection +&hr prior to gold thioglucose administration did not lower the incidence of obesity in surviving mice. The body weight gains were significantly (P < 0.05) greater in all obese compared to nonobese mice in both the gold thioglucose and glucose inhibitor plus gold thioglucose-treated groups. It is noteworthy that in experiment 3, under conditions where the administration of gold thioglucose resulted in obesity in all control animals treated, obese animals exhibited the maximum weight gain. Although not shown in Table I , daily food intake was found to be significantly greater (P < 0.05) in obese compared to nonobese mice in both the gold thioglucose and glucose inhibitor plus gold thioglucose-treated groups.
Content of gold in brain. The total gold content of brains taken from obese mice given gold thioglucose alone was not significantly (P > 0.05) higher than those of similarly treated nonobese mice (Table 2) . Although in certain instances the total gold content of brains from obese animals treated with glucose inhibitor plus gold thioglucase was significantly higher (P < 0.05) than that of brains from nonobese animals, this effect was not consistently reproducible. Compared to gold thioglucosetreated groups of obese and nonobese animals, the brains of mice treated with 2-deoxy-n-glucose and gold thioglucose consistently had significantly (P < 0.05) less gold. The obese and nonobese groups of mice treated with 2-amino-2-deoxy-n-glucose (3 g/kg) and gold thioglucose did not have less gold in the brain than respective groups of animals treated with gold thioglucose alone. Autoradiographic jkdings. Autoradiographs illustrating gold deposits at the site of the hypothalamic lesion are shown in Fig. I . All the brains from mice given gold thioglucose, both with and without a glucose inhibitor, had gold deposits at the site of the hypothalamic lesion. In all instances, the accumulation of gold at this site was less in nonobese than in obese mice. Hypothalamic gold deposits in nonobese mice that had been treated with 2-deoxy-n-glucose and gold thioglucose were scarcely detectable.
The amount of gold deposits at the site of the hypothalamic lesion varied among obese groups on the different treatments as well as among nonobese groups. Compared to those treated with gold thioglucose alone, the mice given 2-deoxy-n-glucose and gold thioglucose and those given 2-amino-2-deoxy-n-glucose (3 g/kg) and gold thioglucose appeared to have diminished gold deposits at the site of the hypothalamic lesion. Since the groups given 2-deoxy-n-glucose plus gold thioglucose and those given 2-amino-2-deoxy-n-glucose (3 g/kg) plus gold thioglucose contained a larger proportion of nonobese mice than the gold thioglucose group, it is apparent that administration of glucose inhibitor decreased gold deposition at the site of the hypothalamic lesion. Mortality.
The mortality following the administration of either gold thioglucose at 800 mg/kg or 2-deoxy-nglucose at I g/kg averaged 7 % (Table   I ).
Mortality after administration
of 2-amino-2-deoxy-n-glucose at 2 g/kg and 3 g/kg averaged 13 %. When 2-deoxy-nglucose-treated animals received gold thioglucose the average mortality rose to 2g %. The highest mortality, which averaged 52 %, was found when gold thioglucose was given to animals receiving rz-amino-a-deoxy-n-glucase (3 g/kg greater than that of the control and 2-amino2deoxy-n-glucose groups (Fig. 2) . When observed, the 2-deoxy-n-glucose-treated animals were found to be continuously eating as opposed to intermittent feeding behavior on the part of control and 2-amino-2-deoxy-nglucose-treated animals. This hyperphagic response was accompanied with a significant (P < 0.01) gain in weight above controls (Fig. 3 ) similar to that noted earlier in experiments r-3. Subsequently, the mice given a-deoxy-nglucose exhibited an anorexia accompanied by a loss in weight before returning to a food intake and weight gain equal to the control groups.
DISCUSSION
In the present studies the administration of 2-deoxy-Dglucose (I g/kg) and 2-amino-2-deoxy-D-glucose (3g/kg) to CBA mice markedly inhibited the incidence of obesity and diminished gold deposition at the site of the hypothalamic lesion resulting from gold thioglucose. In accord with the known inhibitory effects of these inhibitors on cellular entry and oxidation of glucose (I 6, I 7, 31-33), these results may be attributed to competitive inhibition between the glucose inhibitor and gold thioglucose for attachment at hypothalamic glucoreceptor cell sites (23, 25) . Alternatively the glucose inhibitors may be phosphorylated at the intracellular level (I 4, 29, 34), thereby inhibiting further utilization of either glucose or gold thioglucose or both by these cells. The hyperphagia and increased gain in weight noted while a-deoxy-Dglucose was administered to control (untreated) animals supports the contention that this inhibitor may be exerting a direct intracellular effect on the hypothalamic cells of the "satiety center."7 Such an effect would diminish the metabolic activity of these cells, thereby reducing the physiological inhibitory control normally exerted on the more lateral hypothalamic "feeding center." Furthermore, the data would seem to suggest that the hypothalamic cells of the satiety center possess a high affinity
Average daily food intake (zf= SE) of controls, I-deoxy-Dglucose (I g/kg body wt) and 2-amino-2-deoxy-D-glucose (3 g/kg body wt) -treated animals. Each bar represents the mean daily food intake of mice from five cages of animals, each cage housing four or five animals.
for the glucose antimetabolite, z-deoxy-D-glucose, since if cells of both the satiety and feeding centers had an equally high affinity for the inhibitor, one would have expected an aphagic response as has been observed after stereotactically induced lesions in both these areas (I). The role of hyperglycemia in hypothalamic gold uptake and hyperphagia in gold thioglucose-treated mice has recently received some attention by other workers (IO) and should be considered.
In our studies, all mice given a glucose inhibitor had a mild hyperglycemic response. In contrast to animals given a-amino-2-deoxy-Dglucose, 2-deoxy-D-glucose-treated animals exhibited a significantly lower total brain uptake of gold after gold thioglucose administration. Despite these differences, diminished gold deposits at the site of the hypothalamic lesion were noted in the majority of hyperglycemic mice given a-deoxy-D-glucose and 2-amino-2-deoxy-D-glucose after gold thioglucose.
In a recent publication, Edelman et al. (I o) In contrast to our earlier studies, we found gold deposits at the site of the gold thioglucose-induced hypothalamic lesion both in obese and nonobese animals. The accumulation and distribution of gold at the site of the hypothalamic lesion was more extensive in gold thioglucase and glucose inhibitor-gold thioglucose-treated obese than in nonobese mice. Brecher et al. (5), using Swiss albino mice (NIH strain), found hypothalamic lesions in nearly all animals treated with gold thioglucose despite a limited incidence of obesity. They were led to conclude that obesity was correlated with the extent of the lesion, rather than with their presence. Since the ventromedial nuclei (satiety center) were found to be largely spared in the presence of clear-cut gold thioglucose-induced hypothalamic lesions, these workers surmised that the specific affinity of the ventromedial nuclei for the glucose moiety of gold thioglucose cannot account for the hypothalamic localization of the lesions. It should be indicated at this point that although nuclei in the hypothalamic ventromedial area have been implicated in the satiety control mechanism, consideration must be given to the possibility that the satiety center need not be restricted to these nuclei. In this regard, it is of interest that Anand and Brobeck (I) In gold thioglucose-treated mice the extent of the hypothalamic lesion associated with obesity appears to be directly correlated with the quantity of gold that accumulates at this site. In accordance with Brecher et al.
(5) our contention is that the incidence of obesity is governed by the extent of the hypothalamic lesion. However, it is possible that the gold deposited at this site also effects the onset of obesity, apart from the role it plays in inducing the lesion. Since radiofrequency-induced lesions in the ventromedial hypothalamus failed to result in hyperphagia and obesity, Reynolds has suggested that the symptoms of hyperphagia arising from electrolytic lesions may be due to irritant effects produced by electrochemical deposition of metal rather than the result of simple tissue elimination (27, 28) . Although this possi-
